Menu
05/08/2005
Breast cancer HRT risk lower than thought
A woman’s risk of developing breast cancer while taking hormone replacement therapy (HRT) might be lower than previously thought, according to new research.
In a study published in the British Medical Journal, researchers from the New South Wales Breast Cancer Institute estimated a woman’s individual risk of breast cancer up to the age of 79, in relation to HRT, using the latest data.
Researchers found that the cumulative absolute risk of breast cancer fell with increasing age in women who did not take HRT. The team said that the average baseline risk (from 40 – 79) is around 7.2% (1 in 14), which fell to 6.1% (1 in 16) at 50 years and 4.4% (1 in 23) at 60 years.
The team said that the use of HRT only resulted in a slight increase in a woman’s cumulative risk. The study found that the use of oestrogen only hormone replacement or short-term (around five years) use of combined therapy (using both progesterone and oestrogen); beginning at age 50 hardly affects the cumulative risk.
However, the use of combined therapy for around 10 years, was found to increase the cumulative risk to 7.7%, while researchers found that long-term use of oestrogen-only treatments had a “minimal effect” on breast cancer risk.
The study concluded that additional breast cancer risk is greater with combined therapy, especially if it was taken for over five years. However, once HRT is stopped, researchers say, a woman’s breast cancer risk returns to that of a non-user of the same age.
Commenting on the findings of the study, Professor John Boyages, Director of the New South Wales Breast Cancer Institute, said: “Although we found the additional breast cancer risk with hormone replacement therapy for an individual is very small, the effect on the general incidence of breast cancer would be greater, especially in populations with high levels of use.
“The reasons for taking hormone replacement therapy vary and decisions about its use must be made at an individual level. Our analysis provides women and clinicians with better information to make these choices.”
(KMcA/SP)
In a study published in the British Medical Journal, researchers from the New South Wales Breast Cancer Institute estimated a woman’s individual risk of breast cancer up to the age of 79, in relation to HRT, using the latest data.
Researchers found that the cumulative absolute risk of breast cancer fell with increasing age in women who did not take HRT. The team said that the average baseline risk (from 40 – 79) is around 7.2% (1 in 14), which fell to 6.1% (1 in 16) at 50 years and 4.4% (1 in 23) at 60 years.
The team said that the use of HRT only resulted in a slight increase in a woman’s cumulative risk. The study found that the use of oestrogen only hormone replacement or short-term (around five years) use of combined therapy (using both progesterone and oestrogen); beginning at age 50 hardly affects the cumulative risk.
However, the use of combined therapy for around 10 years, was found to increase the cumulative risk to 7.7%, while researchers found that long-term use of oestrogen-only treatments had a “minimal effect” on breast cancer risk.
The study concluded that additional breast cancer risk is greater with combined therapy, especially if it was taken for over five years. However, once HRT is stopped, researchers say, a woman’s breast cancer risk returns to that of a non-user of the same age.
Commenting on the findings of the study, Professor John Boyages, Director of the New South Wales Breast Cancer Institute, said: “Although we found the additional breast cancer risk with hormone replacement therapy for an individual is very small, the effect on the general incidence of breast cancer would be greater, especially in populations with high levels of use.
“The reasons for taking hormone replacement therapy vary and decisions about its use must be made at an individual level. Our analysis provides women and clinicians with better information to make these choices.”
(KMcA/SP)
Related UK National News Stories
Click here for the latest headlines.
11 August 2003
HRT users at greater risk of breast cancer, says research
Some kinds of hormone replacement therapy (HRT) have a much greater effect on a woman's risk of breast cancer than others, according to research published in the Lancet.
HRT users at greater risk of breast cancer, says research
Some kinds of hormone replacement therapy (HRT) have a much greater effect on a woman's risk of breast cancer than others, according to research published in the Lancet.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
08 August 2003
HRT therapy can double breast cancer risk
Certain kinds of hormone replacement therapy (HRT) can double a woman's risk of breast cancer, according to major research study of more than a million women. Researchers found that post-menopausal women using combination HRT were twice as likely to develop breast cancer as non-users.
HRT therapy can double breast cancer risk
Certain kinds of hormone replacement therapy (HRT) can double a woman's risk of breast cancer, according to major research study of more than a million women. Researchers found that post-menopausal women using combination HRT were twice as likely to develop breast cancer as non-users.
01 May 2012
Breast Cancer Can Be Detected Years Before, According To Study
Dr James Flanagan, a Breast Cancer Campaign scientific fellow in the Department of Surgery and Cancer at Imperial College London, has uncovered the first strong evidence that molecular or 'epigenetic' changes in a gene can be associated with breast cancer risk and can be detected many years before breast cancer develops.
Breast Cancer Can Be Detected Years Before, According To Study
Dr James Flanagan, a Breast Cancer Campaign scientific fellow in the Department of Surgery and Cancer at Imperial College London, has uncovered the first strong evidence that molecular or 'epigenetic' changes in a gene can be associated with breast cancer risk and can be detected many years before breast cancer develops.
30 September 2003
'Next big step' in breast cancer treatment launched
Cancer Research UK scientists will today embark on the next big step towards preventing breast cancer with the launch of a major new trial called IBIS II. The 10-year study will test a new drug called anastrozole and involve 10,000 healthy women who are at an increased risk of the disease.
'Next big step' in breast cancer treatment launched
Cancer Research UK scientists will today embark on the next big step towards preventing breast cancer with the launch of a major new trial called IBIS II. The 10-year study will test a new drug called anastrozole and involve 10,000 healthy women who are at an increased risk of the disease.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
